Liquid biopsy for ctDNA detection➡️incidental finding of clonal hematopoiesis (CH) High risk CH ➡️occult hematologic cancers in patients with solid tumors ? MTB Gustave Roussy: 2nd cancer suspected & diagnosed in rare cases JCO Precision Oncology International Society of Liquid Biopsy ascopubs.org/doi/full/10.12…

Large study of RNA-seq in pts w refractory metastatic cancer (n=1031). Pan-cancer analyses. Key msg: high nb of actionable fusions, especially located on PTEN. Certainly a good starting point to evaluate clinical utility of RNA-seq.

« Le Centre national de médecine de précision #PRISM entre dans une nouvelle dimension en devenant un Institut Hospitalo-Universitaire » 📰 Lire le #CommuniquéDePresse ⤵️ gustaveroussy.fr/fr/le-centre-n…

👀 Great work on clonal hematopoiesis in patients enrolled in phase 1 presented by Julieta Rodriguez 🤩#ASCO23 from Gustave Roussy ⚠️ 22% prevalence DMT3A most frequent Tendency on OS ↗️

A stellar panel featuring breast cancer experts Sara Tolaney, @erikahamilton9, and Barbara Pistilli, shedding light on the groundbreaking ADC advancements in breast cancer. Kudos to Barbara Pistilli for the eloquent discussion of the latest advancements in ADCs OncoAlert

First accomplishment of SUMA, our breast cancer national collaborative group! ESMO - Eur. Oncology Congress 2023 here we go. This is the only way: together 💪🏼💪🏼💪🏼Federico Waisberg Gonzalo Gomez Abuin cristian micheri Diego Lucas Kaen

Thank you very much FabriceAndre and Gustave Roussy for this nice opportunity! A big team effort in collaboration with Unicancer CentraleSupélec

#PrecisionMedicine in oncology is evolving towards high-throughput genomics use. This approach may provide vast molecular information in tumors, revealing an average of 4-5 drivers per tumor. Actionable alterations should be prioritized by using validated rankings for treatment

This editorial calls for a strategic shift in our approach to cancers of unknown primary. FabriceAndre Elie Rassy doi.org/10.1093/oncolo…

Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care. Don’t miss the editorial by Drs. Ribeiro, Dixon-Douglas and FabriceAndre that accompanies the latest issue of ESMO Open. esmoopen.com/article/S2059-…

Bravo Jordi Remon ! Congrats!

Bravo Michele Bottosso for this nice review in precision medicine in BC! Here the link to read it doi.org/10.1016/j.esmo…

Outstanding comprehensive talk from ⁦ylt⁩ about applications of MRD in GU cancers during the transatlantic exchanges conference between ⁦Dana-Farber⁩ ⁦Gustave Roussy⁩

Great presentation about MOA/MOR of ADCs from Pr Massard Christophe Massard. Moving forward w UNLOCK📌

Very nice presentation of Dr Barbara Pistilli on WOO trials. So much to do!

Giancarlo Pruneri discussing cancer classification on a tumor agnostic way as pointed out by FabriceAndre Elie Rassy

The 2020 paper by Fernanda Mosele & FabriceAndre on the use of NGS in advanced #Cancer is a landmark in #PrecisionMedicine ⭐️ Now there is an update in press in Annals of Oncology & we get a sneak peek during todays 🇮🇹 #precisionmedicine summit 🤩 #PrecisionMedicine OncoAlert 🚨

Dr Barbara Pistilli et Stefan Michiels : « Le taux de TIL pourrait permettre une désescalade dans le cancer du sein triple négatif » lequotidiendumedecin.fr/specialites/ca…

Just out in #Annals_Oncology, the ESMO recommendations of NGS in 2024 from the PMWG 📢. Don't miss it

Dr Planchard shows data from Icarus with efficacy and biomarkers in #lcsm treated with #datopotamabderuxtecan @asco OncoAlert #asco24